P 135 asthma and copd
1 like372 views
This document provides information about an upcoming conference on asthma and COPD to be held on April 13-14, 2015 in London. It lists key speakers from academic institutions and pharmaceutical companies that will discuss topics such as new therapeutics, personalised treatment approaches, viral exacerbations, and biomarkers. An interactive workshop on functional respiratory imaging is also advertised to take place on April 15. The document provides an agenda with session details and encourages registration by certain dates to receive discounts.
P 135 asthma and copd
- 1. 13 - 14 APRIL 2015 “Excellent meeting” Teva UK SMi presents the 11th annual conference on… Asthma & COPD Exploring the future of therapeutics, diagnosis and care Holiday Inn Regents Park Hotel, London, UK • Sebastian Johnston, Professor of Respiratory Medicine, National Heart and Lung Institute, Imperial College London • Robert Niven, Senior Lecturer in Respiratory Medicine, Manchester University • Neil C Thomson, Professor of Respiratory Medicine, University of Glasgow • Joseph Arron, Associate Director, Biomarker Discovery, Genentech, Inc. • Dirk Smith, Scientific Director, Amgen • Roland Kolbeck, Senior Director, Respiratory, Inflammation & Autoimmunity, MedImmune • Hector Ortega, Medical Director, Respiratory R&D, GSK • Maria Buxton, Consultant Respiratory Physiotherapist, London North West Healthcare NHS Trust BUSINESS BENEFITS FOR 2015: • Explore the future of asthma and COPD treatment from a range of key perspectives • Discover advances in inhaled therapies • Discuss personalised therapy approaches, asthma patient stratification and unmet needs • Share clinical practice ideas to improve the lives of patients • Explore the latest thinking on biomarkers and clinical trial endpoints • Update on mechanisms and treatment for viral induced COPD and asthma exacerbations @SMIPHARM CHAIRS FOR 2015: KEY SPEAKERS INCLUDE: PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP Wednesday 15th April 2015, Holiday Inn Regents Park Hotel, London The power of functional respiratory imaging to define new endpoints and drive successful respiratory drug development Workshop Leaders: Dr. Vos Wim, Chief Technology Officer, FLUIDDA, Prof. Dr. Wilfried De Backer, Director, Professor of Pulmonary Medicine, University Hospital and University of Antwerp 8.30am - 12.30pm www.asthma-copd.co.uk Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 ACADEMIC & GROUP DISCOUNTS AVAILABLE BOOK BY 19TH DECEMBER AND SAVE £400 BOOK BY 30TH JANUARY 200 £FEBRUARY SAVE 100 £AND 27TH SAVE BY BOOK AND
- 2. Asthma & COPD Day One | Monday 13th April 2015 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Sebastian Johnston, Professor of Respiratory Medicine, National Heart and Lung Institute, Imperial College London Asthma Pathways: Lab and Clinic 9.10 OPENING KEYNOTE Children's asthma treatments are like children's clothes: make sure they fit •Severe asthma in children is pathophysiologically different to the adult disease •Before reaching for the monoclonal, think: are the basics right? •When assessing results: did they CONSORT with the right children •Planning trials: does the cap fit? Andrew Bush, Professor of Paediatric Respirology, Imperial College London and Royal Brompton Hospital 9.40 Unravelling mechanisms of asthma exacerbations and implications for the future •Aetiology of asthma exacerbations •Deficient antiviral immunity in asthma •Epithelial immune interactions in asthma exacerbations •Implications for new therapies Sebastian Johnston, Professor of Respiratory Medicine, National Heart and Lung Institute, Imperial College London 10.10 Morning Coffee 10.40 Is neutrophilic/non-eosinophilic inflammation an appropriate therapeutic target in asthma? •Which inflammatory phenotype to target: non-eosinophilic, neutrophilic, Th2-low? •Trials and tribulations with licensed drugs including macrolides for treating neutrophilic/non-eosinophilic asthma •Novel small molecules for treating neutrophilic/non-eosinophilic asthma •Potential role for biological agents for treating neutrophilic/non-eosinophilic asthma Neil C Thomson, Professor of Respiratory Medicine, University of Glasgow 11.10 Mechanisms mediating paediatric severe asthma: translational approaches •Pathology of paediatric severe asthma: inflammation and remodelling •Steroid responsiveness in severe disease •Novel therapeutic targets Sejal Saglani, Reader in Respiratory Paediatrics, Imperial College London 11.40 Cytokine regulation of pulmonary inflammation and remodelling in asthma •Can asthma phenotypes be modelled in vivo? •Is airway remodelling dependent on inflammation? •How do genes and environment affect development of pathology? •Novel therapeutic avenues Clare Lloyd, Professor of Respiratory Immunology, Imperial College London Register online at: www.asthma-copd.co.uk • Alternatively fax y 12.10 Networking Lunch 1.10 PARTNERSHIPS FOCUS Changing role of patient charities in research - what can we offer? •Benefits of working with charities to patients and wider society •What value can patient charities bring to multi-partner collaborations? •The Asthma UK approach to establishing research partnerships with industry •Examples of large collaborative research programmes that Asthma UK is involved in and future ways of working Samantha Walker, Executive Director, Research & Policy, Asthma UK Personalised Therapeutics 1.40 Enabling targeted therapy for severe asthma through molecular phenotyping and biomarker development • Asthma heterogeneity impacts target, patient, and outcome selection •A clinically valid biomarker comprises both the thing being measured and the assay used to measure it •How to prove biomarker selection hypotheses in clinical studies •Beyond type 2 inflammation: new insights into asthma phenotypes Joseph Arron, Associate Director, Biomarker Discovery, Genentech, Inc. 2.10 New therapeutic approaches for asthma: It's all about the airways • New biology is emphasizing the importance of the epithelium and innate immune pathways as key orchestrators of asthma-associated pathology • What clues have genetics provided regarding key pathways and risk factors? • Asthma is not a single disease- the importance of stratification and biomarkers • Emerging targets and biomarker approaches from the new science Dirk Smith, Scientific Director, Amgen 2.40 Eosinophilic inflammation and exacerbations of asthma and COPD: A fatal liaison •Management of acute exacerbations in Asthma and COPD •The role of eosinophilic inflammation in Asthma and COPD •Development of monoclonal antibodies for the management of severe Asthma and COPD •The need for personalized health care Roland Kolbeck, Senior Director, Respiratory, Inflammation & Autoimmunity, MedImmune 3.10 Afternoon Tea 3.40 Is the severe asthma phenotype stable? • Learnings from cluster analyses • Steroid-resistant phenotype in severe asthma • Challenges and opportunities in clinical research Hector Ortega, Medical Director, Respiratory R&D, GSK 4.10 The ADEPT study: airways disease endotyping for personalized therapeutics in asthma and COPD •It’s clear not all drugs work in all people; are you surprised? •Janssen wished to build up an internal database for asthma and COPD to interrogate current and future therapeutic targets •We recruited 150 asthmatics and 30 healthy controls in PART 1 and 60 COPD and 60 healthy controls in Part 2. Most subjects had bronchoscopies •We have already gained great insights and the analysis has only just begun! Philip E Silkoff, Senior Director, Immunology, Pulmonary Disease Area, Janssen Inc. 4.40 Chairman's Closing Remarks and Close of Day One Sebastian Johnston, Professor of Respiratory Medicine, National Heart and Lung Institute, Imperial College London SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk Official Media Partners
- 3. Asthma & COPD Day Two | Tuesday 14th April 2015 8.30 Registration & Coffee Robert Niven, Senior Lecturer in Respiratory Medicine, Manchester University 9.00 Chairman's Opening Remarks Sebastian Johnston, Professor of Respiratory Medicine, National Heart and Lung Institute, Imperial College London 9.10 ENABLING TECHNOLOGY FOCUS Always on, always with you. The role of personal technology and the digital economy in respiratory health • Why will we see increasingly widespread adoption of new personal health technologies? • There’s an app for that: medical “apps” are likely to have a significant role in respiratory health in the future • Google knows, do you? The trail left by your daily interactions contains valuable health related data • Discuss examples of smart devices (including smart inhalers) providing information that isn’t apparent to healthcare professionals John Blakey, Senior Clinical Lecturer, Liverpool School of Tropical Medicine James Pinchin, Horizon DERC, University of Nottingham Viruses in Asthma and COPD 9.50 Viruses in asthma and COPD • Contribution of viruses to exacerbations in asthma and COPD • Mechanisms of virus-induced exacerbations • Viral/bacterial co-infection • Future developments Patrick Mallia, Senior Clinical Lecturer, Imperial College London 10.20 Development of antivirals for the treatment/prevention of virus induced exacerbations of asthma and COPD • Unmet clinical need • Target mechanisms: pathogen or host? • Therapies in development • Future therapeutic options Phillip Monk, Chief Scientific Officer, Synairgen 10.50 Morning Coffee 11.20 Drug development challenges associated with inhaled and intranasal antivirals • Device and dosing considerations • Indication and patient segmentation • Trial setting and endpoints Staffan Edsbacker, Global Project Director & Associate Professor, AstraZeneca R&D Mölndal & University of Lund 11.50 Round Table Discussion: Challenges and choices in stratified asthma therapeutics • How many interleukin targeting MABS will be enough? • What are the unmet needs in asthma and what is the future for these groups? Robert Niven, Senior Lecturer in Respiratory Medicine, Manchester University 12.30 Networking Lunch 1.30 ENABLING TECHNOLOGY FOCUS Imaging lung structure and function with hyperpolarised gas MRI • Outline the role of functional lung imaging with multi-nuclear MRI in obstructive airways disease • Emphasise the sensitivity of novel MRI methods to early lung disease • Demonstrate the application of the methods in assessment of novel respiratory therapeutics Jim Wild, Professor of Magnetic Resonance Physics, University of Sheffield COPD: Present and Future 2.00 Ceramide 1-phosphate (C1P), a potential new therapeutic target for COPD • C1P reduces lung inflammation • C1P promotes cell growth, survival and migration • The mechanism whereby C1P exerts its anti-inflammatory actions involve inhibition of sphingomyelinase and serine palmitoyl transferase activities, reduction of pro-inflammatory cytokines, and inhibition of NF-kB • C1P analogs are promising tools for developing new strategies to treat COPD Antonio Gomez-Munoz, Professor of Biochemistry and Molecular Biology, University of the Basque Country 2.30 RPL554 as a novel treatment for severe COPD • Unmet medical need in COPD • RPL554 as a treatment of COPD exacerbations • Additional potential indications for RPL554 Jan-Anders Karlsson, CEO, Verona Pharma 3.00 Afternoon Tea 3.30 Pulmonary rehabilitation in the real world • Research vs Real Life • Drop out – is there an answer? • Mapping PR in London • Commissioning PR Maria Buxton, Consultant Respiratory Physiotherapist, London North West Healthcare NHS Trust 4.00 CLOSING ADDRESS COPD: Unmet need and challenges in NHS Care • What are the key areas of unmet clinical need for COPD clinical care? • What are the barriers to access for new drugs in current NHS practice? • Who is prescribing new drugs in the NHS? • Which aspects of COPD urgently require new pharmaceutical approaches? John Hurst, Consultant in Respiratory Medicine, University College London 4.30 Chairman's Closing Remarks and Close of Day Two Robert Niven, Senior Lecturer in Respiratory Medicine, Manchester University Supported by Interested in promoting your services to this market? Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162 or email tarri@smi-online.co.uk our registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
- 4. HALF-DAY POST-CONFERENCE AM WORKSHOP Wednesday 15th April 2015 8.30am - 12.30pm Holiday Inn Regents Park Hotel, London, UK The power of functional respiratory imaging to define new endpoints and drive successful respiratory drug development Workshop Leaders: Dr. Vos Wim, Chief Technology Officer, FLUIDDA, Prof. Dr. Wilfried De Backer, Director, Professor of Pulmonary Medicine, University Hospital and University of Antwerp Overview of workshop: This workshop focusses on overcoming the difficulties that companies face when registering new respiratory drugs. It demonstrates that functional respiratory imaging is able to provide new detailed insights and clear performance measures that can be vital for a successful outcome of the drug development process. You should attend if you are interested in the potential of sensitive innovative endpoints to provide decisions making process in the early and clinical development phases of a device or drug to improve commercial outcomes Who should attend this workshop: • Decision makers in the development trajectory for respiratory drugs • Individuals interested in alternative outcome parameters in respiratory medicine Programme: 8.30 Registration and coffee 9.00 Opening remarks 9.15 The current development trajectory of respiratory drugs 10.15 Functional respiratory imaging (FRI) 10.45 Coffee break 11.15 The current status of FRI • Scientific evidence • Regulatory standpoint 11.45 Future perspectives of FRI • Drug development • Clinical practice 12.15 Closing remarks 12.30 End of workshop About the host: Wim Vos is the CTO of FLUIDDA. Over the last 10 years he has been responsible for the development of functional imaging based outcome parameters in respiratory drug development. He is author of over 25 journal publications and over 100 conference abstracts. Wilfried De Backer is the director of the department of pulmonary medicine at the University Hospital and full professor at the University of Antwerp. He also served as an expert for EMA and was head of the clinical physiology, sleep and pulmonary circulation assembly at ERS. He is author of numerous books and publications and is considered an authority in his field. About he ogranisation: FLUIDDA is the leading R&D company in the field of quantitative image analysis for respiratory diseases. Its proprietary FRI technology offers a unique entry point into personalized medicine by providing patient specific imaging biomarkers. Implementing FRI in early clinical research results in a cost-effective and time-saving screening of the most promising respiratory drugs.
- 5. SMI'S PHARMACEUTICAL PORTFOLIO 2015 JANUARY Pharmaceutical Microbiology 21st – 22nd January 2015 Marriott Regents Park, London Social Media in the Pharma Industry 21st – 22nd January 2015 Marriott Regents Park, London Pre Filled Syringes 28th – 29th January 2015 Marriott Regents Park, London FEBRUARY Parallel Trade 9th – 10th February 2015 Holiday Inn Regents Park, London Advances and Progress in Drug Design 16th – 17th February 2015 Marriott Regents Park, London RNAi Therapeutics 16th – 17th February 2015 Marriott Regents Park, London MARCH Superbugs & Superdrugs – A focus on Antibacterials 25th – 26th March 2015 Holiday Inn Regents Park, London Paediatric Clinical Trials 25th – 26th March Holiday Inn Regents Park, London APRIL Asthma & COPD 13th – 14th April 2015 Holiday Inn Regents Park, London Adaptive Designs 20th – 21st April 2015, London Pre Filled Syringes USA 27th – 28th April 2015, Iselin, USA Lyophilisation and Freeze Drying USA 29th – 30th April 2015, Iselin, USA SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
- 6. Conference: Monday 13th & Tuesday 14th April 2015, Holiday Inn Regents Park Hotel, London, UK Workshop: Wednesday 15th April 2015, London 4 WAYS TO REGISTER www.asthma-copd.co.uk FAX your booking form to +44 (0) 870 9090 712 PHONE on +44 (0) 870 9090 711 ASTHMA & COPD POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK Unique Reference Number Our Reference LVP-135 DELEGATE DETAILS Please complete fully and clearly in capital letters. Please photocopy for additional delegates. Title: Forename: Surname: Job Title: Department/Division: Company/Organisation: Email: Company VAT Number: Address: Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: Mobile: Switchboard: Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. ACCOUNTS DEPT Title: Forename: Surname: Email: Address (if different from above): Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: VENUE Holiday Inn Regents Park Hotel, Carburton Street, London, W1W 5EE □ Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712 Terms and Conditions of Booking Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received. Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate. Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability. Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter. □ Book by 19th December 2014 to receive £400 off the conference price □ Book by 30th January 2015 to receive £200 off the conference price □ Book by 27th February 2015 to receive £100 off the conference price EARLY BIRD DISCOUNT CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee Total □ Conference and 1 Workshop £2098.00 +VAT £2517.60 □ Conference only £1499.00 +VAT £1798.80 □ 1 Workshop only £599.00 +VAT £718.80 PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80 The conference fee includes refreshments, lunch, conference papers, and access to the Document Portal. Presentations that are available for download will be subject to distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post conference. DOCUMENTATION I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation Price Total □ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80 □ The Conference Presentations – paper copy £499.00 - £499.00 (or only £300 if ordered with the Document Portal) PAYMENT Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-135 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment: □ UK BACS Sort Code 300009, Account 00936418 □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18 □ Cheque We can only accept Sterling cheques drawn on a UK bank. □ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges. Card No: □□□□ □□□□ □□□□ □□□□ Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card Cardholder’s Name: Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. Card Billing Address (If different from above): VAT VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here. ______________________________________________________________________________________________ If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk